Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.
Identifieur interne : 000246 ( Main/Corpus ); précédent : 000245; suivant : 000247Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.
Auteurs : Cynthia Nassim ; Shane Christensen ; Dan Henry ; Sandra Holmes ; Matthew Hohenboken ; Niranjan Kanesa-ThasanSource :
- The Pediatric infectious disease journal [ 1532-0987 ] ; 2012.
English descriptors
- KwdEn :
- Adjuvants, Immunologic (administration & dosage), Adjuvants, Immunologic (adverse effects), Antibodies, Viral (blood), Child (MeSH), Child, Preschool (MeSH), Female (MeSH), Germany (MeSH), Hemagglutination Inhibition Tests (MeSH), Humans (MeSH), Immunization (adverse effects), Immunization (methods), Influenza A Virus, H1N1 Subtype (immunology), Influenza Vaccines (administration & dosage), Influenza Vaccines (adverse effects), Influenza Vaccines (immunology), Influenza, Human (prevention & control), Male (MeSH), Polysorbates (administration & dosage), Polysorbates (adverse effects), Single-Blind Method (MeSH), Squalene (administration & dosage), Squalene (adverse effects), Time Factors (MeSH), United States (MeSH).
- MESH :
- chemical , administration & dosage : Adjuvants, Immunologic, Influenza Vaccines, Polysorbates, Squalene.
- chemical , adverse effects : Adjuvants, Immunologic, Influenza Vaccines, Polysorbates, Squalene.
- chemical , blood : Antibodies, Viral.
- chemical , immunology : Influenza Vaccines.
- geographic : Germany, United States.
- adverse effects : Immunization.
- immunology : Influenza A Virus, H1N1 Subtype.
- methods : Immunization.
- prevention & control : Influenza, Human.
- Child, Child, Preschool, Female, Hemagglutination Inhibition Tests, Humans, Male, Single-Blind Method, Time Factors.
Abstract
BACKGROUND
In the development of pediatric A/H1N1 influenza vaccines, this study was performed to identify antigen and adjuvant doses providing optimal immunogenicity and antibody persistence to ensure long-term immunity after immunization with an adjuvanted A/H1N1 vaccine in children 3 to <9 years of age.
METHODS
Healthy children (N = 1357) were immunized with 1 of 8 investigational vaccine formulations ranging in antigen (3.75-30 µg) and MF59 adjuvant (Novartis Vaccines, Marburg, Germany; 0, 50 and 100% of standard dose). Each participant received 2 vaccine doses given 3 weeks apart. Immunogenicity was analyzed by hemagglutination inhibition assay in sera drawn 3, 4 and 6 weeks after first vaccination. Long-term antibody persistence was assessed 6 and 12 months after immunization. Vaccine safety was monitored throughout the study.
RESULTS
All MF59-adjuvanted vaccines were well tolerated and highly immunogenic, with adjuvanted formulations inducing antibody titers statistically superior to those of the nonadjuvanted vaccines. Each MF59-adjuvanted vaccine met all the US and European licensure criteria for influenza vaccines 3 weeks after the administration of a single dose; all nonadjuvanted formulations failed to meet licensure criteria at this time point. Antibody titers in response to a single vaccination with 7.5 µg antigen and a full dose of MF59 continued to meet all US and European licensure criteria up to 1 year after immunization.
CONCLUSION
A single dose of vaccine containing 7.5 µg A/California/7/2009 (H1N1) antigen and a full dose of MF59 adjuvant was found to be optimal for children 3 to <9 years of age.
DOI: 10.1097/INF.0b013e31824b9545
PubMed: 22418661
Links to Exploration step
pubmed:22418661Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.</title>
<author><name sortKey="Nassim, Cynthia" sort="Nassim, Cynthia" uniqKey="Nassim C" first="Cynthia" last="Nassim">Cynthia Nassim</name>
<affiliation><nlm:affiliation>Nassim and Associates, Pediatric Medicine, New Albany, IN, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Christensen, Shane" sort="Christensen, Shane" uniqKey="Christensen S" first="Shane" last="Christensen">Shane Christensen</name>
</author>
<author><name sortKey="Henry, Dan" sort="Henry, Dan" uniqKey="Henry D" first="Dan" last="Henry">Dan Henry</name>
</author>
<author><name sortKey="Holmes, Sandra" sort="Holmes, Sandra" uniqKey="Holmes S" first="Sandra" last="Holmes">Sandra Holmes</name>
</author>
<author><name sortKey="Hohenboken, Matthew" sort="Hohenboken, Matthew" uniqKey="Hohenboken M" first="Matthew" last="Hohenboken">Matthew Hohenboken</name>
</author>
<author><name sortKey="Kanesa Thasan, Niranjan" sort="Kanesa Thasan, Niranjan" uniqKey="Kanesa Thasan N" first="Niranjan" last="Kanesa-Thasan">Niranjan Kanesa-Thasan</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2012">2012</date>
<idno type="RBID">pubmed:22418661</idno>
<idno type="pmid">22418661</idno>
<idno type="doi">10.1097/INF.0b013e31824b9545</idno>
<idno type="wicri:Area/Main/Corpus">000246</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000246</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.</title>
<author><name sortKey="Nassim, Cynthia" sort="Nassim, Cynthia" uniqKey="Nassim C" first="Cynthia" last="Nassim">Cynthia Nassim</name>
<affiliation><nlm:affiliation>Nassim and Associates, Pediatric Medicine, New Albany, IN, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Christensen, Shane" sort="Christensen, Shane" uniqKey="Christensen S" first="Shane" last="Christensen">Shane Christensen</name>
</author>
<author><name sortKey="Henry, Dan" sort="Henry, Dan" uniqKey="Henry D" first="Dan" last="Henry">Dan Henry</name>
</author>
<author><name sortKey="Holmes, Sandra" sort="Holmes, Sandra" uniqKey="Holmes S" first="Sandra" last="Holmes">Sandra Holmes</name>
</author>
<author><name sortKey="Hohenboken, Matthew" sort="Hohenboken, Matthew" uniqKey="Hohenboken M" first="Matthew" last="Hohenboken">Matthew Hohenboken</name>
</author>
<author><name sortKey="Kanesa Thasan, Niranjan" sort="Kanesa Thasan, Niranjan" uniqKey="Kanesa Thasan N" first="Niranjan" last="Kanesa-Thasan">Niranjan Kanesa-Thasan</name>
</author>
</analytic>
<series><title level="j">The Pediatric infectious disease journal</title>
<idno type="eISSN">1532-0987</idno>
<imprint><date when="2012" type="published">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (administration & dosage)</term>
<term>Adjuvants, Immunologic (adverse effects)</term>
<term>Antibodies, Viral (blood)</term>
<term>Child (MeSH)</term>
<term>Child, Preschool (MeSH)</term>
<term>Female (MeSH)</term>
<term>Germany (MeSH)</term>
<term>Hemagglutination Inhibition Tests (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Immunization (adverse effects)</term>
<term>Immunization (methods)</term>
<term>Influenza A Virus, H1N1 Subtype (immunology)</term>
<term>Influenza Vaccines (administration & dosage)</term>
<term>Influenza Vaccines (adverse effects)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Male (MeSH)</term>
<term>Polysorbates (administration & dosage)</term>
<term>Polysorbates (adverse effects)</term>
<term>Single-Blind Method (MeSH)</term>
<term>Squalene (administration & dosage)</term>
<term>Squalene (adverse effects)</term>
<term>Time Factors (MeSH)</term>
<term>United States (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adjuvants, Immunologic</term>
<term>Influenza Vaccines</term>
<term>Polysorbates</term>
<term>Squalene</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Adjuvants, Immunologic</term>
<term>Influenza Vaccines</term>
<term>Polysorbates</term>
<term>Squalene</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Germany</term>
<term>United States</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Immunization</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Immunization</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Child</term>
<term>Child, Preschool</term>
<term>Female</term>
<term>Hemagglutination Inhibition Tests</term>
<term>Humans</term>
<term>Male</term>
<term>Single-Blind Method</term>
<term>Time Factors</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b>
</p>
<p>In the development of pediatric A/H1N1 influenza vaccines, this study was performed to identify antigen and adjuvant doses providing optimal immunogenicity and antibody persistence to ensure long-term immunity after immunization with an adjuvanted A/H1N1 vaccine in children 3 to <9 years of age.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>METHODS</b>
</p>
<p>Healthy children (N = 1357) were immunized with 1 of 8 investigational vaccine formulations ranging in antigen (3.75-30 µg) and MF59 adjuvant (Novartis Vaccines, Marburg, Germany; 0, 50 and 100% of standard dose). Each participant received 2 vaccine doses given 3 weeks apart. Immunogenicity was analyzed by hemagglutination inhibition assay in sera drawn 3, 4 and 6 weeks after first vaccination. Long-term antibody persistence was assessed 6 and 12 months after immunization. Vaccine safety was monitored throughout the study.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>All MF59-adjuvanted vaccines were well tolerated and highly immunogenic, with adjuvanted formulations inducing antibody titers statistically superior to those of the nonadjuvanted vaccines. Each MF59-adjuvanted vaccine met all the US and European licensure criteria for influenza vaccines 3 weeks after the administration of a single dose; all nonadjuvanted formulations failed to meet licensure criteria at this time point. Antibody titers in response to a single vaccination with 7.5 µg antigen and a full dose of MF59 continued to meet all US and European licensure criteria up to 1 year after immunization.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSION</b>
</p>
<p>A single dose of vaccine containing 7.5 µg A/California/7/2009 (H1N1) antigen and a full dose of MF59 adjuvant was found to be optimal for children 3 to <9 years of age.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22418661</PMID>
<DateCompleted><Year>2012</Year>
<Month>07</Month>
<Day>16</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1532-0987</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>31</Volume>
<Issue>4</Issue>
<PubDate><Year>2012</Year>
<Month>Apr</Month>
</PubDate>
</JournalIssue>
<Title>The Pediatric infectious disease journal</Title>
<ISOAbbreviation>Pediatr. Infect. Dis. J.</ISOAbbreviation>
</Journal>
<ArticleTitle>Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.</ArticleTitle>
<Pagination><MedlinePgn>e59-65</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/INF.0b013e31824b9545</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In the development of pediatric A/H1N1 influenza vaccines, this study was performed to identify antigen and adjuvant doses providing optimal immunogenicity and antibody persistence to ensure long-term immunity after immunization with an adjuvanted A/H1N1 vaccine in children 3 to <9 years of age.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Healthy children (N = 1357) were immunized with 1 of 8 investigational vaccine formulations ranging in antigen (3.75-30 µg) and MF59 adjuvant (Novartis Vaccines, Marburg, Germany; 0, 50 and 100% of standard dose). Each participant received 2 vaccine doses given 3 weeks apart. Immunogenicity was analyzed by hemagglutination inhibition assay in sera drawn 3, 4 and 6 weeks after first vaccination. Long-term antibody persistence was assessed 6 and 12 months after immunization. Vaccine safety was monitored throughout the study.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">All MF59-adjuvanted vaccines were well tolerated and highly immunogenic, with adjuvanted formulations inducing antibody titers statistically superior to those of the nonadjuvanted vaccines. Each MF59-adjuvanted vaccine met all the US and European licensure criteria for influenza vaccines 3 weeks after the administration of a single dose; all nonadjuvanted formulations failed to meet licensure criteria at this time point. Antibody titers in response to a single vaccination with 7.5 µg antigen and a full dose of MF59 continued to meet all US and European licensure criteria up to 1 year after immunization.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A single dose of vaccine containing 7.5 µg A/California/7/2009 (H1N1) antigen and a full dose of MF59 adjuvant was found to be optimal for children 3 to <9 years of age.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nassim</LastName>
<ForeName>Cynthia</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Nassim and Associates, Pediatric Medicine, New Albany, IN, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Christensen</LastName>
<ForeName>Shane</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Henry</LastName>
<ForeName>Dan</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y"><LastName>Holmes</LastName>
<ForeName>Sandra</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Hohenboken</LastName>
<ForeName>Matthew</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kanesa-Thasan</LastName>
<ForeName>Niranjan</ForeName>
<Initials>N</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Pediatr Infect Dis J</MedlineTA>
<NlmUniqueID>8701858</NlmUniqueID>
<ISSNLinking>0891-3668</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C089950">MF59 oil emulsion</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011136">Polysorbates</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>7QWM220FJH</RegistryNumber>
<NameOfSubstance UI="D013185">Squalene</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006385" MajorTopicYN="N">Hemagglutination Inhibition Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011136" MajorTopicYN="N">Polysorbates</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016037" MajorTopicYN="N">Single-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013185" MajorTopicYN="N">Squalene</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year>
<Month>3</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2012</Year>
<Month>3</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2012</Year>
<Month>7</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">22418661</ArticleId>
<ArticleId IdType="doi">10.1097/INF.0b013e31824b9545</ArticleId>
<ArticleId IdType="pii">00006454-201204000-00015</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeAllemagneV4/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000246 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000246 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= GrippeAllemagneV4 |flux= Main |étape= Corpus |type= RBID |clé= pubmed:22418661 |texte= Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:22418661" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a GrippeAllemagneV4
This area was generated with Dilib version V0.6.35. |